Open access · OA via Europe PMC

SelO-mediated nicotinamide adenine dinucleotide hydrolysis and its implications for metabolic therapies.

Clinical and translational medicine · 2026

Mitochondrial dysfunction

Abstract

This 2026 Clinical and Translational Medicine article examines SelO-mediated nicotinamide adenine dinucleotide hydrolysis and its metabolic implications.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: Europe PMC
DOI: 10.1002/ctm2.70773
Canonical: link ↗
Fetched: 2026-10-07 MST

Cite this

APA

T, Z., T, W., & Y., F. (2026). SelO-mediated nicotinamide adenine dinucleotide hydrolysis and its implications for metabolic therapies. <em>Clinical and translational medicine</em>. https://doi.org/10.1002/ctm2.70773

Vancouver

T Z, T W, Y. F. SelO-mediated nicotinamide adenine dinucleotide hydrolysis and its implications for metabolic therapies. Clinical and translational medicine. 2026. doi:10.1002/ctm2.70773.

BibTeX

@article{zhang2026SelOme, title = {SelO-mediated nicotinamide adenine dinucleotide hydrolysis and its implications for metabolic therapies.}, author = {Zhang T and Wang T and Fu Y.}, journal = {Clinical and translational medicine}, year = {2026}, doi = {10.1002/ctm2.70773}, }